Related Experiment Video

Updated: Jan 6, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K

Olutasidenib: an Achilles' heel for IDH1-mutated MDS?

Laura Wiser1, Curtis Lachowiez1,2

  • 1Department of Medicine, Oregon Health & Science University, Portland, OR.

Blood Advances
|October 20, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K

Related Experiment Videos

Last Updated: Jan 6, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

Articles linked to this work by shared authors, journal, and citation graph.

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

Blood·2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Models, Models, Everywhere: But Which One Should Guide Care?

Blood cancer discovery·2026

Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.

Blood·2025

Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.

Blood cancer discovery·2025

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Central Nervous System Involvement in Children with Hemophagocytic Lymphohistiocytosis: an HLH-2004 Study Report.

Blood advances·2026

Risk Factors for Pediatric Acute Chest Syndrome Utilizing Machine Learning Techniques.

Blood advances·2026

Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis.

Blood advances·2026

Richter transformation: emerging immunologic strategies beyond chemoimmunotherapy.

Blood advances·2026

Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma.

Blood advances·2026

A Comprehensive Review of T-Cell Lymphoma Following CAR T-Cell Immunotherapy.

Blood advances·2026

The Timing and Characteristics of Supplemental Indications for Medicines.

The American journal of managed care·2026

New-onset alopecia areata during calcitonin gene-related peptide inhibitor therapy: first reported case.

Dermatology reports·2026

Therapeutic effect of Fuzheng Yixin decoction on cardiac insufficiencythe soluble guanylyl cyclase-cyclic guanosine monophosphate-protein kinase G pathway in a doxorubicin-induced dilated cardiomyopathy rat model.

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan·2026

Shaofu Zhuyu decoction can inhibit the progression of endometriosis fibrosis through the transforming growth factor-β1/ smads signaling pathway mediated by 5' adenosine monophosphate-activated protein kinase.

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan·2026

Baihe Dihuang decoction activates cannabinoid type 2 receptor to regulate microglial polarization and alleviate anxiety-like behavior in chronic restraint stress mice.

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan·2026

Real-World Treatment Patterns and Clinical Outcomes with Cyclosporine 0.1% in Semifluorinated Alkane for Dry Eye Disease.

Clinical ophthalmology (Auckland, N.Z.)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us